![]() | |
Clinical data | |
---|---|
Other names | TC-5619 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C22H23N3O2 |
Molar mass | 361.445 g·mol−1 |
3D model ( JSmol) | |
| |
(verify) |
Bradanicline ( INN, [1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [2] Phase I clinical trials were completed successfully, and it was in phase II trials. [3]
In May 2011, AstraZeneca declined to exercise its right to license the compound. [4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults. [5] It was being studied for cognitive and memory enhancement. [6]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013. [7] It was also discontinued for ADHD. [7]